Scarica l'app Stockscreener
2.85
3.06%
-0.09
Dopo l'orario di chiusura:
2.85
Precedente Chiudi:
$2.94
Aprire:
$2.99
Volume 24 ore:
795.31K
Relative Volume:
1.13
Capitalizzazione di mercato:
$198.98M
Reddito:
$63.63M
Utile/perdita netta:
$10.62M
Rapporto P/E:
57.00
EPS:
0.05
Flusso di cassa netto:
$-8.64M
1 W Prestazione:
+9.20%
1M Prestazione:
+12.65%
6M Prestazione:
+163.89%
1 anno Prestazione:
+141.53%
Intervallo 1D:
$2.84
$3.04
Intervallo di 1 settimana:
$2.50
$3.04
Portata 52W:
$0.8214
$3.04
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Nome
Protalix BioTherapeutics Inc.
Settore
Industria
Telefono
972 4 988 9488
Indirizzo
2 Snunit Street, Science Park PO Box 455, Karmiel
Confronta PLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.85 | 198.98M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-17 | Reiterato | Rodman & Renshaw | Buy |
| 2016-04-04 | Iniziato | Rodman & Renshaw | Buy |
| 2015-04-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2014-11-12 | Reiterato | R. F. Lafferty | Buy |
| 2014-01-24 | Iniziato | R. F. Lafferty | Buy |
| 2012-05-02 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Reiterato | Oppenheimer | Outperform |
| 2012-04-30 | Downgrade | Auriga | Buy → Hold |
| 2011-10-13 | Iniziato | Morgan Joseph | Hold |
| 2011-03-17 | Downgrade | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Reiterato | Oppenheimer | Outperform |
| 2010-10-14 | Reiterato | UBS | Buy |
| 2009-12-02 | Reiterato | Hapoalim | Outperform |
| 2009-09-22 | Iniziato | Canaccord Adams | Buy |
| 2009-09-02 | Iniziato | Hapoalim | Outperform |
| 2008-12-01 | Reiterato | Oppenheimer | Outperform |
| 2008-03-11 | Iniziato | UBS | Buy |
| 2007-11-20 | Iniziato | CIBC Wrld Mkts | Sector Outperform |
Mostra tutto
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
PLX’s earnings estimates: Are they on track to meet expectations? - uspostnews.com
Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Protalix CFO Eyal Rubin to resign in six months By Investing.com - Investing.com Nigeria
Protalix BioTherapeutics' CFO Rubin to Leave - MarketWatch
Protalix stock soars to 52-week high, hits $2.76 By Investing.com - Investing.com South Africa
Eyal Rubin Resigns As CFO Of Protalix BiotherapeuticsSEC Filing - marketscreener.com
Protalix CFO Eyal Rubin to resign in six months - Investing.com
Protalix stock soars to 52-week high, hits $2.76 - Investing.com
The growth track for Protalix BioTherapeutics Inc (PLX) has changed recently - Sete News
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline - Seeking Alpha
Fabry Disease Treatment Market Opportunity and Forecast Report 2025-2034 Featuring Amicus Therapeutics, Avrobio, Freeline, Idorsia, ISU Abxis, JCR, Novartis, Pfizer, Protalix, Sanofi, Takeda, Viatris - Yahoo Finance
Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 - BioSpace
Fabry Disease Treatment Market Deep Research 2025-2032 | - openPR.com
Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news
Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st
Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive financial news
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Financial Times
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive financial news
FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World
Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World
Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors
Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA
Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news
Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey
PLX: 2024 Results - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... - Yahoo
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics Reports Record Revenue and Clinical Progress - TipRanks
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth By Investing.com - Investing.com Canada
Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030 - MSN
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond - Benzinga
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth - Investing.com
Protalix BioTherapeutics Inc. (DE) (PLX) reports earnings - Quartz
Protalix Q4 Earnings Fall, Stock Up In Pre-market - Nasdaq
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - GuruFocus.com
StockNews.com Upgrades Protalix BioTherapeutics (NYSE:PLX) to “Strong-Buy” - Defense World
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - Kilgore News Herald
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - Quantisnow
Protalix BioTherapeutics to Report FY2024 Earnings on March 17 - Stock Titan
Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter
Protalix BioTherapeutics Inc. Azioni (PLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):